Mepsevii

Vestronidase alfa, the active ingredient in Mepsevii, is a recombinant enzyme presented as a 5 mg/mL lyophilized powder for solution for infusion for intravenous use. It treats mucopolysaccharidosis type VII (Sly syndrome) by providing the missing beta‑glucuronidase enzyme in affected patients.

GNH USA supplies Mepsevii as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Mepsevii provides enzyme replacement therapy for the lysosomal storage disorder mucopolysaccharidosis type VII. - Mucopolysaccharidosis type VII (Sly syndrome): reduces glycosaminoglycan storage in tissues. - Mucopolysaccharidosis type VII (Sly syndrome): improves organ function and growth parameters. - Mucopolysaccharidosis type VII (Sly syndrome): decreases progression of skeletal abnormalities.

Mepsevii may be associated with infusion‑related reactions and other adverse events.

Common Side Effects: - Fever: transient elevation of body temperature during or after infusion. - Chills: shaking sensation commonly reported. - Rash: mild skin erythema at infusion site. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hypotension: significant drop in blood pressure during infusion. - Elevated liver enzymes: increase in ALT/AST indicating hepatic stress. - Antibody formation: development of anti‑drug antibodies that may reduce efficacy.

Before initiating Mepsevii therapy, clinicians should consider several precautionary measures. - Infusion monitoring: observe patients closely for reactions during and after administration. - Premedication: consider antihistamines or antipyretics to reduce infusion‑related symptoms. - Liver function: assess baseline hepatic enzymes and monitor periodically. - Immunogenicity: test for anti‑drug antibodies if clinical response diminishes. - Hypersensitivity: avoid use in patients with known allergy to the product or its excipients. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mepsevii can interact with other medicines, primarily through immune modulation or overlapping safety profiles.

Major Interactions (Avoid): - Live vaccines: concurrent administration may increase risk of infection; avoid during therapy. - Concomitant enzyme replacement products: may lead to additive immune responses.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., azathioprine, methotrexate): may increase infection susceptibility; monitor patient. - Antipyretics (e.g., acetaminophen): may mask fever, a key infusion reaction sign; observe closely. - Drugs affecting liver enzymes (e.g., strong CYP inducers): may alter hepatic monitoring parameters; adjust labs accordingly.